



Acute bacterial meningitis

Emma C. Wall^{a,b}, Jia Mun Chan^b, Eliza Gil^b, and Robert S. Heyderman^b

Purpose of review

Community-acquired bacterial meningitis is a continually changing disease. This review summarises both dynamic epidemiology and emerging data on pathogenesis. Updated clinical guidelines are discussed, new agents undergoing clinical trials intended to reduce secondary brain damage are presented.

Recent findings

Conjugate vaccines are effective against serotype/serogroup-specific meningitis but vaccine escape variants are rising in prevalence. Meningitis occurs when bacteria evade mucosal and circulating immune responses and invade the brain: directly, or across the blood–brain barrier. Tissue damage is caused when host genetic susceptibility is exploited by bacterial virulence. The classical clinical triad of fever, neck stiffness and headache has poor diagnostic sensitivity, all guidelines reflect the necessity for a low index of suspicion and early Lumbar puncture. Unnecessary cranial imaging causes diagnostic delays. cerebrospinal fluid (CSF) culture and PCR are diagnostic, direct next-generation sequencing of CSF may revolutionise diagnostics. Administration of early antibiotics is essential to improve survival. Dexamethasone partially mitigates central nervous system inflammation in high-income settings. New agents in clinical trials include C5 inhibitors and daptomycin, data are expected in 2025.

Summary

Clinicians must remain vigilant for bacterial meningitis. Constantly changing epidemiology and emerging pathogenesis data are increasing the understanding of meningitis. Prospects for better treatments are forthcoming.

Keywords

antibiotics, dexamethasone, meningitis, pathogenesis, vaccines

INTRODUCTION

Acute bacterial meningitis (ABM) is a disease with rapid onset, outbreak and epidemic potential, and high rates of mortality and morbidity [1,2]. Considerable advances have been made in the last 30 years towards epidemic management and disease control through vaccination, and understanding the contributions of both host and pathogen to clinical outcomes. In this review, we will summarise the rapidly changing epidemiology of ABM in the context of new vaccines. We will show how new unbiased genomics technologies are revealing specific host–pathogen interactions that cause inflammation and brain damage. Additionally, we will summarise which new adjunctive treatments are in development and describe how the current Severe Acute Respiratory Syndrome CoronaVirus2 (SARS-CoV2) pandemic may impact on the WHO's efforts to defeat meningitis by 2030.

EPIDEMIOLOGY AND IMPACT OF VACCINATION

Community-acquired bacterial meningitis is predominantly caused by three pathogens, *Streptococcus*

pneumoniae, *Neisseria meningitidis* and *Haemophilus influenzae* type B. Additionally, *Streptococcus suis* in Southeast Asia, *Listeria monocytogenes*, Group B Streptococci, and Gram-negative bacteria such as *Escherichia coli* and *Klebsiella pneumoniae*, cause meningitis in specific groups, including neonates, pregnant women, transplant recipients and older adults [3]. Worldwide, the number of reported cases of bacterial meningitis to global surveillance sites rose between 2006 and 2016, with incidence strongly

^aFrancis Crick Institute and ^bNIHR Mucosal Pathogens Research Unit, Department of Infection, Division of Infection and Immunity, University College London, London, UK

Correspondence to Emma C. Wall, NE424, Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Tel: +44 203 7960000; e-mail: emma.wall@crick.ac.uk

Curr Opin Neurol 2021, 34:386–395

DOI:10.1097/WCO.0000000000000934

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

KEY POINTS

- The epidemiology of bacterial meningitis is regional and highly dynamic, influenced by vaccines, climate, latitude, population movement, viral infections and poverty.
- Serotype/serogroup specific conjugate vaccines are highly effective in preventing meningitis, but serotype replacement is increasing, effectively limiting the impact of conjugate vaccines on disease incidence
- Host and pathogen factors influence clinical outcomes, host genetic susceptibility to poor outcome from pneumococcal meningitis is linked to genes involved in NF- κ B signalling and endothelial integrity.
- Dexamethasone improves outcome in pneumococcal meningitis in high-income settings only, new agents targeted on the host response are currently in clinical trials.

related to poverty (SDI) [3]. However, the geographical incidence varies significantly. In well-resourced settings, ABM incidence has fallen to below 0.5–1.5/100 000 population [4,5,6^{***}]. Contrastingly, in countries in the African Sahel region, where epidemic meningitis due to *N. meningitidis* and *S. pneumoniae* persists, incidence reaches 1000/100 000 cases [3,7–9]. Beyond the meningitis belt, the incidence in Africa approaches 2.5–25/100 000 per population [10,11].

Bacterial meningitis is globally associated with cooler, drier seasons [9]. It is likely that climate change will impact on meningitis incidence but modelling data are lacking [11]. Social distancing measures introduced to mitigate the spread of SARS-CoV2 during the CoronaVirus Infectious Diseases 2019 pandemic are also predicted to lead to a 20–30% decrease in meningitis incidence [12^{*},13].

Global meningitis epidemiology is highly dynamic; changes in the last 25 years amongst adults and children have been influenced by the widespread use of conjugate vaccines [14–16], the HIV-1 epidemic [17–19], the roll-out of antiretroviral and antibacterial treatment including prevention of mother-to-child transmission [20,21], and significant progress on development and poverty reduction strategies (SDG), including improved maternal and neonatal care [22].

Vaccination remains the most important pillar of the WHO-led roadmap towards defeating meningitis by 2030 [23]. A summary of all available vaccines against the three common pathogens is given in Table 1.

Streptococcus pneumoniae

S. pneumoniae is the commonest cause of ABM world-wide. Reports of reduction in paediatric invasive pneumococcal disease (IPD), following pneumococcal conjugate vaccine introduction in higher-income countries, were rapidly followed by evidence of herd immunity in the wider adult population, particularly the elderly [24–26]. Incidence of *S. pneumoniae* meningitis is estimated to have fallen by 48% in children [14,16,27]. However, parallel reports have emerged of IPD, including meningitis, caused by nonvaccine serotypes [14,28–30]. To mitigate against serotype replacement and better prevent meningitis, new approaches to pneumococcal vaccine design are under development, including whole capsule and protein vaccines [31–34,35^{*}].

Neisseria meningitidis

Conjugate meningococcal vaccines are highly effective in preventing meningitis caused by individual serogroups. Serogroup C Incidence has declined dramatically following the introduction of Men-C vaccine in children in many high-income countries [36–38]. Epidemic meningitis caused by serogroup A in the Sahel region of Africa has been dramatically reduced by low-cost MenAfriVac serogroup A conjugate vaccine by 92% [39,40]. However, virulent clones of other serogroups have subsequently emerged (C, W, X) and epidemics of meningococcal meningitis continue to occur in the Sahel [41,42].

As serogroup C disease declined, serogroup B emerged as the leading cause of meningococcal meningitis in high SDI countries [15]. In 2015, the UK government introduced protein-based serogroup B vaccine 4CMenB (Bexsero) to all children under 2 years. UK cases of invasive serogroup B in children have declined 75% with an estimated overall vaccine efficacy of 54% [43]. However, disease due to other serogroups including W and Y remains problematic. MenC conjugate vaccine has now been replaced with quadrivalent MenACWY vaccine for all teenagers and young adults in the UK [38].

Haemophilus influenzae

Hib vaccination in 1989 led to dramatic reductions in paediatric meningitis between 75 and 95% [44,45]. Subsequently, Hib meningitis has virtually been eliminated globally in countries with effective Expanded Programme of Immunisations (EPI), but persists where vaccination coverage is poor including India, Nigeria, Pakistan and the Democratic Republic of Congo [16,44,46,47]. Hib conjugate vaccines are estimated to have reduced Hib meningitis by 49% globally 2000–2016 [3], and paediatric

Table 1. Currently available vaccinations against meningitis-pathogens

Vaccine formulation	Vaccine name	Serotypes covered	Protein conjugate	Commercially available vaccine
<i>Streptococcus pneumoniae</i>				
Polysaccharide	PPV-23	1, 2, 3, 4, 5, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F	NA	Pneumovax
Conjugate	PCV-7	4, 6B, 9V, 14, 18C, 19F, 23F	CRM197 ^a	Prevenar
Conjugate	PCV-10	1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F	Protein D, diphtheria toxoid, tetanus toxoid	Synflores
Conjugate	PCV-10	1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F	CRM197	Pneumosil
Conjugate	PCV-13	1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F	CRM197	Prevenar 13
<i>Neisseria meningitidis</i>				
Conjugate	MenACWY	ACWY	CRM197, diphtheria toxoid	Menactra, Menveo Serum Institute of India (in development)
Polysaccharide	MPSV4	ACWY	NA	Menimmune
Conjugate	MenC	C	CRM197 or tetanus toxoid	Menitorix, NeisVac-C, Menjugate, Meningitec
Conjugate	Hib_MenCY-TT	CY, Hib	Tetanus toxoid	MenHibrix
Conjugate	Men A	A	Tetanus toxoid	MenAfriVac
Protein	Men B bivalent vaccine	B	Not used	Trumemba
Protein	4CMenB	B	Not used	Bexsero
<i>Haemophilus influenzae</i>				
Conjugate	Monovalent	Type b	CRM197	Menitorix, Pediacel

^aCRM197 = nontoxic variant of diphtheria toxin.

NA, Not available; PCV, Pneumococcal Conjugate Vaccine; PPV, Pneumococcal Polysaccharide Vaccine.

deaths by 90% over the same time period [16]. However, it is concerning that non-type b stains such as Hia are emerging [42].

Group B *Streptococcus*

Streptococcus agalactiae (Group B *Streptococcus*, GBS) primarily causes meningitis in neonates but also causes sepsis in older adults with co-morbidities and young adults who have consumed contaminated fish [48]. Serotypes Ia, Ib, II, III and V account for 98% of human carriage serotypes isolated globally [49]. Clonal complex 17 (CC17) strains have been shown to be hypervirulent, accounting for more than 80% of the disease [50,51]. GBS disease-causing lineages have distinct niche adaptation and virulence characteristics [52,53]. The most promising strategy to eliminate neonatal meningitis caused by GBS is vaccination in pregnancy, trials are ongoing [54–57].

PATHOGENESIS

The pathogenesis of most ABM follows a sequential pattern: nasopharyngeal colonization, bloodstream

invasion across the mucosa, circulation of bacteria to the central nervous system (CNS), and subsequent CNS entry [58[•],59]. In ABM caused by *L. monocytogenes*, GBS and *S. suis*, bacteraemia has a gastrointestinal or genitourinary tract source [52,60,61]. Occasionally, ABM is acquired through direct CNS invasion through the cribriform plate [62,63]. In the majority of immunocompetent individuals, colonisation of the nasopharynx by *S. pneumoniae* and *N. meningitidis* is cleared by mucosal immunity, despite epithelial invasion [58[•]]. Co-infection with *S. pneumoniae* and respiratory viruses such as influenza causes a heightened inflammatory state associated with both pneumococcal and meningococcal invasion [64–66], indeed preceding influenza is associated with seasonal ABM [11,67[•]].

Bacteraemia usually precedes translocation across the blood–brain barrier (BBB) and/or blood–cerebrospinal fluid barrier into the CNS. Under basal conditions, the CNS environment is under continuous immunological surveillance [68]. This is achieved through the complexity of the BBB, where pericytes, astrocytes, microglia and specialised endothelial cells work in synergy




FIGURE 1. Model of BBB environment during bacterial meningitis. ABM pathogen (depicted here as blue diplococci) in the bloodstream cross the capillary endothelium using both transcellular and paracellular routes. Bacteria may also be carried across the BBB by infiltrating phagocytes (Trojan Horse strategy). Recognition of the pathogen via sensing of PAMPs leads to the activation of resident immune cells such as microglia, macrophages, astrocytes and pericytes and production of DAMPs. These cells produce a coordinated inflammatory response to contain bacteria and recruit more neutrophils to the CSF compartment. This host response, while important for killing bacteria, activates a fibrinolytic and coagulation cascade. When advanced, these processes lead to sustained tissue damage, BBB breakdown and leakage, causing death or lifelong neurological sequelae in survivors. ABM, acute bacterial meningitis; BBB, blood–brain barrier.

to both resist pathogen invasion and kill bacteria on entry [68] (Fig. 1). Bacteria breach the BBB by interacting with laminin receptors and exploiting endocytic pathways, for example via Platelet Activating Factor Receptor signalling [69–72] (Fig. 1). However, mechanisms by which ABM-causing bacteria subvert CNS barriers to cause meningitis are not fully described.

In the 10–30% of ABM cases without concurrent bacteraemia [73], bacteria may interact with gangliosides, adhere to the olfactory bulb, invade the olfactory epithelium and directly translocate to the brain [63,74–77]. Pneumococcal strains causing nonhematogenous meningitis tend to be less frequently studied using bacteraemia-based animal models [75–77].

Inflammation and exacerbation of tissue damage in acute bacterial meningitis

Bacteria replicate rapidly in the relatively immune-privileged CNS compartment [78], releasing

Pathogen Associated Molecular Pattern (PAMP) that bind to toll-like receptors including 2,3,4 and 9, triggering the release of Damage-Associated Molecular Pattern Signallings (DAMPs) via Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NF- κ B) activation [79–82]. The subsequent release of extracellular cytokines and chemokines including Chemokine family Ligand 8 and cerebrospinal fluid (CSF)-3 drives a rapid influx of neutrophils to the CSF compartment [83⁸⁴].

Bacterial PAMPs and virulence proteins exert direct damage on the delicate structures of the CNS. Pneumococcal virulence factors, including capsule and pneumolysin, reduce microglia motility and chemotaxis [85⁸⁶]. Pneumolysin, a cytolysin and Toll Like Receptor 4 agonist is implicated in directly toxic effects on host cells, particularly within the BBB and hippocampus [86,87]. Others stimulate Cerebral Binding Protein (CBP) and receptor for advanced glycation end products (RAGE), increasing Tumour Necrosis Factor alpha (TNF- α) levels and promoting BBB disruption [88,89⁹⁰].

Host-detection of bacteria within the CNS triggers a highly inflammatory, and predominately ineffective host response, associated with further tissue damage. Sustained inflammation exacerbates tissue damage, leading to death or irreversible neurological damage [73,90,91]. Neutrophil infiltration is important for bacterial elimination [92]. However, neutrophils can directly damage the CNS [93]. Neutrophil extracellular traps (NETs) unexpectedly impaired CNS pneumococcal clearance and increased inflammatory damage in an experimental model [83^{***}]. Damaging DAMPs released both from neutrophil degranulation and NF- κ B signalling include myeloperoxidase, matrix-metalloproteinases, TNF- α and prostaglandins [94[■],95,96,97[■]]. Neutrophil-mediated inflammation is strongly associated with dysfunctional coagulation and fibrinolytic cascade in the CNS, including an excess of the anaphylatoxin complement C5 [98].

Clinical improvement with dexamethasone adjunctive therapy in both Hib and pneumococcal meningitis demonstrates the importance of host-mediated inflammation in ABM [99,100]. Dexamethasone may reduce NF- κ B signalling and cytokine release [101].

Leveraging new technology to interrogate acute bacterial meningitis pathogenesis

Bacterial genome-wide association studies (GWAS) have revealed loci that are implicated in invasiveness, tissue tropism and the ability to cause CNS disease [102^{***},103^{***},104,105]. Single Nucleotide Polymorphisms (SNPs) in the *raf* operon determine pneumococcal tropism for ear/brain or lungs in an intranasal challenge model [106[■],107]. Additionally, SNPs in *raf* modulated neutrophil recruitment, leading to strain-dependent clearance [106[■]].

Gene expression in *S. pneumoniae* is niche dependent, highlighting the importance of bacterial metabolism in pathogenesis [108,109^{***}]. In a quantitative proteomics study of ABM, the abundance of pneumococcal protein Elongation Factor Tu in CSF associated with severity in human disease [97[■]]. In a murine model, proteins AliB and competence peptides were implicated in pathogenesis [110]. Joint human–pathogen GWAS studies of meningitis patients suggest that genetic differences in the host response exert greater effects on susceptibility and disease severity than bacterial genotype. This GWAS identified variants in the *CCDC3* gene associated with disease severity [102^{***}]. *CCDC3* is a multifunction gene involved in the metabolism and suppression of NF- κ B–TNF α activation in endothelial cells [111].

NEW DIRECTIONS IN DIAGNOSTICS AND CLINICAL MANAGEMENT

Early recognition and initiation of appropriate antimicrobials are essential to minimise death and complications from ABM. The differential diagnosis in patients presenting with headache, fever, neck stiffness or altered mental state is broad: the classical meningitis triad has limited diagnostic sensitivity [112]. A high index of clinical suspicion is thus required to diagnose ABM [113]. Lumbar puncture is essential, and should be undertaken promptly before CSF is rendered sterile by broad-spectrum antibiotics [114].

Many patients with ABM present with an altered level of consciousness, leading clinicians to frequently request cranial imaging prior to diagnostic lumbar puncture. Early Lumbar puncture (LP) is strongly associated with higher diagnostic yield from the CSF; delays in LP for cranial imaging lead to substantial reductions in yield from either CSF bacterial culture or PCR [114]. Delays to diagnosis are linked to worse clinical outcomes [114–116]. Cranial imaging (either CT or MRI) in patients with clear clinical signs and symptoms of meningitis without focal neurology is thus not recommended in the majority of patients with suspected ABM [117,118]. CT has poor inter-reporting reliability to predict the risk of cerebral herniation in ABM [119]. The American, British and European infection societies meningitis guidelines all recommend immediate LP in cases of suspected ABM without delay for CT/MRI in immunocompetent adults with suspected ABM who have a stable GCS of $\geq 12/15$ without seizures [119–123]. Important contraindications to LP include shock, respiratory compromise, or coagulopathy.

The diagnosis of ABM is dependent on the analysis of CSF. The leukocyte count remains the strongest predictive value of ABM. Diagnostic models including clinical, CSF and blood data show little additional benefit beyond clinical judgement [111]. Antibiotic administration prior to LP commonly renders the CSF sterile, thus clinicians are increasingly dependent on diagnostic PCR. Recent data suggest that while small multiplex panels targeting Hib, meningococci and pneumococci are highly sensitive and specific [123], larger panels that include viral, nosocomial and rarer community-acquired pathogens have varying sensitivity and specificity and are not currently recommended [124]. More recently, direct next-generation sequencing (NGS) and metagenomics of CSF have been proposed to detect pathogens in cases with a high index of clinical suspicion of ABM but negative PCR tests [125^{***}]. While this approach is promising,

constraints around cost, bioinformatics expertise and clinically relevant turnaround times have limited clinical use of NGS to date [124].

All guidelines recommend patients with suspected ABM should receive parenteral antibiotics within 1 h. However, only 46% of patients in a clinical research study were reported to meet this target, limited by delays in the emergency department [126,127]. Antibiotic choice should be determined by patient risk group, patient allergies, and local guidelines informed by epidemiology, including antimicrobial resistance. Penicillin resistance in *S. pneumoniae* is 15–20% in some settings, but remains <5% in *N. meningitidis* [128,129]. However, quinolone resistance in *N. meningitidis* reaches 70% in Southeast Asia [15,130]. Diagnostic uncertainty in culture-negative meningitis often leads to prolonged dual antibiotic and antiviral therapies, which may be associated with nosocomial complications [114,131[■]].

Adjunctive therapies

Adjunctive treatments are designed to reduce secondary inflammation in ABM and decrease the morbidity associated with CNS tissue damage. Inflammation is associated with secondary complications of ABM, including death, deafness, stroke, epilepsy and learning difficulties [91,131[■],132–134]. Delayed cerebral thrombosis is a rare complication of ABM that can occur up to 2 weeks post-admission [135,136].

In hospitals in high-income settings, patients presenting with suspected pneumococcal meningitis should receive adjunctive dexamethasone to reduce mortality [90,137]. In low-income settings, dexamethasone is only indicated in cases of suspected *S. suis* meningitis in Southeast Asia to reduce deafness [137,138]. In other settings, particularly in Low and Middle Income Countries in Africa, dexamethasone is ineffective and should not be given [139].

Other previously tested adjuncts, including hypothermia and glycerol, have been shown to be potentially harmful and should not be administered [140,141].

Emerging therapeutic targets

Empirical antibiotic treatment in most centres for suspected ABM is the third-generation cephalosporin, ceftriaxone [92]. However, bacterial lysis by ceftriaxone releases DAMPs that may prolong damaging inflammation even as bacteria killed [88]. Research in animal models has strongly suggested bacteriostatic antibiotics are associated with less

CNS inflammation and improve outcomes [142]. In clinical practice, there are little data to suggest different clinical outcomes occur between bacteriostatic vs. bactericidal antibiotics [143]. As such, there are continued efforts to develop alternatives that reduce sequelae in survivors. A phase 2 clinical trial evaluating the adjunctive use of a nonlytic antibiotic, daptomycin, for pneumococcal meningitis is currently underway (ClinicalTrials.gov identifier NCT03480191). Adjunctive administration of daptomycin may dampen the inflammatory effects of ceftriaxone through currently unknown mechanisms [144].

The damaging coagulation and fibrinolytic cascade in CSF are triggered partly by excess complement C5 [98]. Inhibition of C5 improved outcomes in a murine model, clinical trials of C5 antagonists are currently underway [145].

Newer therapeutic agents with intriguing survival data in animal models are not yet in clinical trials. These include DNase-1, targeted at disrupting ineffective NETosis, the possible neuroprotective effects of metformin, and matrix-metalloproteinase inhibitors targeted on preventing enzymatic tissue breakdown [83[■],146–148]. Proposed adjunctive antipneumococcal therapy includes targeting pneumolysin and P4, a pneumococcal peptide that may inhibit replication [149,150].

CONCLUSION

Community-acquired bacterial meningitis presents ongoing formidable epidemiological and clinical challenges. The ability of meningitis-causing pathogens to evolve in the ecological niche of the nasopharynx during carriage, and escape serotype-specific vaccines has led to new strategies to eliminate disease carriage through serotype-independent vaccination. The outcome of CNS host-pathogen interactions determines clinical sequelae, influenced by host genetic susceptibility.

CSF analysis is essential to make a diagnosis of ABM, leukocyte count remains the most effective predictor of ABM over newer models. Nonindicated cranial imaging introduces significant diagnostic delays. Multiplex PCR panels have increasing utility in ABM diagnostics, however NGS remains a research tool.

Patients with ABM continue to experience significant complications, including death, stroke and deafness. Adjunctive dexamethasone improves survival in high-income countries only, the results of clinical trials of more targeted approaches are awaited. Effective and affordable, pan-serogroup vaccination remains a crucial goal if we are to eliminate this devastating disease.

Acknowledgements

Financial support and sponsorship

E.W. is supported by a postdoctoral clinical research fellowship from the Francis Crick Institute, and the National Institute for Health Research University College London Hospitals Department of Health's NIHR Biomedical Research Centre. E.C. and R.H. are funded by the National Institute for Health Research (NIHR) (project reference 16/136/46) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK government.

E.C. and R.H. are funded by the Medical Research Council grant number MR/T016329/1 and the National Institute for Health Research (NIHR) (project reference 16/136/46) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK government.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Lorton F, Chalumeau M, Assathiany R, *et al.* Vaccine-preventable severe morbidity and mortality caused by meningococcus and pneumococcus: a population-based study in France. *Paediatr Perinat Epidemiol* 2018; 32:442–447.
2. Boeddha NP, Schlapbach LJ, Driessen GJ, *et al.* Mortality and morbidity in community-acquired sepsis in European pediatric intensive care units: a prospective cohort study from the European Childhood Life-threatening Infectious Disease Study (EUCLIDS). *Crit Care* 2018; 22:143. doi: 10.1186/s13054-018-2052-7.
3. Collaborators GBDM. Global, regional, and national burden of meningitis, 1999–2016: a systematic analysis for the Global Burden of Disease Study. *Lancet Neurol* 2018; 17:1061–1082.
4. Erdem H, Inan A, Guven E, *et al.* The burden and epidemiology of community-acquired central nervous system infections: a multinational study. *Eur J Clin Microbiol Infect Dis* 2017; 36:1595–1611.
5. Hasbun R, Rosenthal N, Balada-Llasat JM, *et al.* Epidemiology of meningitis and encephalitis in the United States, 2011–2014. *Clin Infect Dis* 2017; 65:359–363.
6. Koelman DLH, van Kassel MN, Bijlsma MW, *et al.* Changing epidemiology of bacterial meningitis since introduction of conjugate vaccines: three decades of national meningitis surveillance in The Netherlands. *Clin Infect Dis* 2020. doi: 10.1093/cid/ciaa1774. Online ahead of print.

Updated European meningitis epidemiology showing *S. pneumoniae* meningitis increasing in adults in Europe.

7. Daugla DM, Gami JP, Gamougam K, *et al.* Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. *Lancet* 2014; 383:40–47.
8. Gessner BD, Mueller JE, Yaro S. African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adults. *BMC Infect Dis* 2010; 10:22. doi: 1471-2334-10-22.
9. Paireau J, Chen A, Broutin H, *et al.* Seasonal dynamics of bacterial meningitis: a time-series analysis. *Lancet Glob Health* 2016; 4: e370–e377.

10. Wall EC, Everett DB, Mukaka M, *et al.* Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and Haemophilus influenzae type b vaccination, 2000–2012. *Clin Infect Dis* 2014; 58:e137–e145.
11. Mazamay S, Broutin H, Bompangue D. The environmental drivers of bacterial meningitis epidemics in the Democratic Republic of Congo, central Africa. *PLoS Negl Trop Dis* 2020; 14:e0008634. doi: 10.1371/journal.pntd.0008634.
12. Amin-Chowdhury Z, Collins S, Sheppard C, *et al.* Characteristics of invasive pneumococcal disease (IPD) caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in England; prospective observational cohort study, 2014–18. *Clin Infect Dis* 2020. doi: 10.1093/cid/ciaa043. Online ahead of print.

Landmark data from the UK showing nonvaccine serotypes cause more severe IPD.

13. Luciani L, Ninove L, Zandotti C, Nougairade A. COVID-19 pandemic and its consequences disrupt epidemiology of enterovirus meningitis, South-East France. *J Med Virol* 2021; 93:1929–1931.
14. Oligbu G, Collins S, Djennad A, *et al.* Effect of pneumococcal conjugate vaccines on pneumococcal meningitis, England and Wales, July 1, 2000–June 30, 2016. *Emerg Infect Dis* 2019; 25:1708–1718.
15. Acevedo R, Bai X, Borrow R, *et al.* The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. *Expert Rev Vaccines* 2019; 18:15–30.
16. Wahl B, O'Brien KL, Greenbaum A, *et al.* Burden of *Streptococcus pneumoniae* and *Haemophilus influenzae* type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. *Lancet Glob Health* 2018; 6:e744–e757.
17. Ganiem AR, Parwati I, Wisaksana R, *et al.* The effect of HIV infection on adult meningitis in Indonesia: a prospective cohort study. *AIDS* 2009; 23:2309–2316.
18. Schutte CM, Van der Meyden CH, Magazi DS. The impact of HIV on meningitis as seen at a South African Academic Hospital (1994 to 1998). *Infection* 2000; 28:3–7.
19. van Aalst M, Lotsch F, Spijker R, *et al.* Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis. *Travel Med Infect Dis* 2018; 24:89–100.
20. Hasperhoven GF, Al-Nasiry S, Bekker V, *et al.* Universal screening versus risk-based protocols for antibiotic prophylaxis during childbirth to prevent early-onset group B streptococcal disease: a systematic review and meta-analysis. *BJOG* 2020; 127:680–691.
21. Murray CJ, Ortblad KF, Guinovart C, *et al.* Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study. *Lancet* 2014; 384:1005–1070.
22. Liu L, Oza S, Hogan D, *et al.* Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the sustainable development goals. *Lancet* 2016; 388:3027–3035.
23. WHO. Defeating bacterial meningitis by 2030. 2020. Available from: <https://www.who.int/emergencies/diseases/meningitis/meningitis-2030.pdf>. [Accessed January 2021].
24. Harboe ZB, Dalby T, Weinberger DM, *et al.* Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. *Clin Infect Dis* 2014; 59:1066–1073.
25. Bijlsma MW, Brouwer MC, Kasaanmoentalib ES, *et al.* Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. *Lancet Infect Dis* 2016; 16:339–347.
26. Hanquet G, Krizova P, Valentiner-Branth P, *et al.* Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. *Thorax* 2019; 74:473–482.
27. Ouldali N, Levy C, Varon E, *et al.* Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. *Lancet Infect Dis* 2018; 18:983–991.
28. Koelman DLH, Brouwer MC, van de Beek D. Resurgence of pneumococcal meningitis in Europe and Northern America. *Clin Microbiol Infect* 2020; 26:199–204.
29. Ladhani SN, Collins S, Djennad A, *et al.* Rapid increase in nonvaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. *Lancet Infect Dis* 2018; 18:441–451.
30. Ciruela P, Izquierdo C, Broner S, *et al.* The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. *Vaccine* 2018; 36:7744–7752.
31. Odotula A, Ota MOC, Antonio M, *et al.* Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of *Streptococcus pneumoniae* in infants: a phase 2, randomized, controlled, observer-blind study. *Vaccine* 2017; 35:2531–2542.
32. Hammit LL, Campbell JC, Borys D, *et al.* Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: a phase IIb randomized study. *Vaccine* 2019; 37:7482–7492.

33. Converso TR, Assoni L, Andre GO, *et al.* The long search for a serotype independent pneumococcal vaccine. *Expert Rev Vaccines* 2020; 19:57–70.
34. Schumann B, Reppe K, Kaplonek P, *et al.* Development of an efficacious, semisynthetic glycoconjugate vaccine candidate against *Streptococcus pneumoniae* serotype 1. *ACS Cent Sci* 2018; 4:357–361.
35. Ramos-Sevillano E, Ercoli G, Felgner P, *et al.* Preclinical development of virulence attenuated *Streptococcus pneumoniae* strains able to enhance protective immunity against pneumococcal infection. *Am J Respir Crit Care Med* 2020. doi: 10.1164/rccm.202011-4161LE. Online ahead of print.
- New data suggesting attenuated pneumococcal whole cell vaccines enhance PCV effects.
36. Bai X, Borrow R, Bukovski S, *et al.* Prevention and control of meningococcal disease: updates from the Global Meningococcal Initiative in Eastern Europe. *J Infect* 2019; 79:528–541.
37. Li J, Shao Z, Liu G, *et al.* Meningococcal disease and control in China: findings and updates from the Global Meningococcal Initiative (GMI). *J Infect* 2018; 76:429–437.
38. Findlow H, Campbell H, Lucidarme J, *et al.* Serogroup C *Neisseria meningitidis* disease epidemiology, seroprevalence, vaccine effectiveness and waning immunity, England, 1998/99 to 2015/16. *Eur Commun Dis Bull* 2019; 24. doi: 10.2807/1560-7917.ES.2019.24.1.1700818.
39. Daugla DM, Gami JP, Gamougam K, *et al.* Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. *Lancet* 2014; 383:40–47.
40. Trotter CL, Lingani C, Fernandez K, *et al.* Impact of MenAfriVac in nine countries of the African meningitis belt, 2010–15: an analysis of surveillance data. *Lancet Infect Dis* 2017; 17:867–872.
41. Lamelas A, Hauser J, Dangy JP, *et al.* Emergence and genomic diversification of a virulent serogroup W:ST-2881 (CC175) *Neisseria meningitidis* clone in the African meningitis belt. *Microb Genom* 2017; 3:e000120. doi: 10.1099/mgen.0.000120.
42. WHO. Weekly feedback bulletin on cerebrospinal meningitis. In: Africa, editor. Geneva 2020. <https://www.who.int/publications/m/item/meningitis-weekly-bulletin-28-september-to-1-november-2020>
43. Ladhani SN, Andrews N, Parikh SR, *et al.* Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. *N Engl J Med* 2020; 382:309–317.
44. Murphy TV, White KE, Pastor P, *et al.* Declining incidence of *Haemophilus influenzae* type b disease since introduction of vaccination. *JAMA* 1993; 269:246–248.
45. Peltola H. Worldwide *Haemophilus influenzae* type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. *Clin Microbiol Rev* 2000; 13:302–317.
46. Ali M, Chang BA, Johnson KW, Morris SK. Incidence and aetiology of bacterial meningitis among children aged 1–59 months in South Asia: systematic review and meta-analysis. *Vaccine* 2018; 36:5846–5857.
47. Adegbola RA, Secka O, Lahai G, *et al.* Elimination of *Haemophilus influenzae* type b (Hib) disease from the Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. *Lancet* 2005; 366:144–150.
48. Barkham T, Zadoks RN, Azmai MNA, *et al.* One hypervirulent clone, sequence type 283, accounts for a large proportion of invasive *Streptococcus agalactiae* isolated from humans and diseased tilapia in Southeast Asia. *PLoS Negl Trop Dis* 2019; 13:e0007421. doi: 10.1371/journal.pntd.0007421.
49. Russell NJ, Seale AC, O'Driscoll M, *et al.* Maternal colonization with Group B *Streptococcus* and serotype distribution worldwide: systematic review and meta-analysis. *Clin Infect Dis* 2017; 65(Suppl_2):S100–S111.
50. Lamy MC, Dramsi S, Billoet A, *et al.* Rapid detection of the 'highly virulent' group B *Streptococcus* ST-17 clone. *Microbes Infect* 2006; 8:1714–1722.
51. Shabayek S, Spellerberg B. Group B streptococcal colonization, molecular characteristics, and epidemiology. *Front Microbiol* 2018; 9:437. doi: 10.3389/fmicb.2018.00437.
52. Gori A, Harrison OB, Mlia E, *et al.* Pan-GWAS of *Streptococcus agalactiae* highlights lineage-specific genes associated with virulence and niche adaptation. *mBio* 2020; 11. doi: 10.1128/mBio.00728-20.
53. Chan JM, Gori A, Nobbs AH, Heyderman RS. Streptococcal serine-rich repeat proteins in colonization and disease. *Front Microbiol* 2020; 11:593356. doi: 10.3389/fmicb.2020.593356.
54. Berardi A, Cassetti T, Creti R, *et al.* The Italian arm of the PREPARE study: an international project to evaluate and license a maternal vaccine against Group B *Streptococcus*. *Ital J Pediatr* 2020; 46:160. doi: 10.1186/s13052-020-00923-3.
55. Abu-Raya B, Maertens K, Edwards K, *et al.* Global perspectives on immunization during pregnancy and priorities for future research and development: an international consensus statement. *Front Immunol* 2020; 11:1282. doi: 10.3389/fimmu.2020.01282.
56. Heyderman RS, Madhi SA, French N, *et al.* Group B *Streptococcus* vaccination in pregnant women with or without HIV in Africa: a nonrandomised phase 2, open-label, multicentre trial. *Lancet Infect Dis* 2016; 16:546–555.
57. Carreras-Abad C, Ramkhalawon L, Heath PT, Le Doare K. A vaccine against Group B *Streptococcus*: recent advances. *Infect Drug Resist* 2020; 13:1263–1272.
58. Weight CM, Venturini C, Pojar S, *et al.* Microinvasion by *Streptococcus pneumoniae* induces epithelial innate immunity during colonisation at the human mucosal surface. *Nat Commun* 2019; 10:3060. doi: 10.1038/s41467-019-11005-2.
- First data showing *S. pneumoniae* subverting the mucosal epithelium and the associated innate immune response.
59. Tuomanen EI. Perspective of a pediatrician: shared pathogenesis of the three most successful pathogens of children. *Front Cell Infect Microbiol* 2020; 10:585791. doi: 10.3389/fcimb.2020.585791.
60. Kremer PH, Lees JA, Koopmans MM, *et al.* Benzalkonium tolerance genes and outcome in *Listeria monocytogenes meningitis*. *Clin Microbiol Infect* 2017; 23:265.e1–265.e7.
61. van Kassel MN, van Haeringen KJ, Brouwer MC, *et al.* Community-acquired group B streptococcal meningitis in adults. *J Infect* 2020; 80:255–260.
62. Sjolinder H, Jonsson AB. Olfactory nerve—a novel invasion route of *Neisseria meningitidis* to reach the meninges. *PLoS One* 2010; 5:e14034. doi: 10.1371/journal.pone.0014034.
63. van Ginkel FW, McGhee JR, Watt JM, *et al.* Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. *PNAS* 2003; 100:14363–14367.
64. Aguilera ER, Lenz LL. Inflammation as a modulator of host susceptibility to pulmonary influenza, pneumococcal, and co-infections. *Front Immunol* 2020; 11:105. doi: 10.3389/fimmu.2020.00105.
65. Loh E, Kugelberg E, Tracy A, *et al.* Temperature triggers immune evasion by *Neisseria meningitidis*. *Nature* 2013; 502:237–240.
66. Jochems SP, Marcon F, Carniel BF, *et al.* Inflammation induced by influenza virus impairs human innate immune control of pneumococcus. *Nat Immunol* 2018; 19:1299–1308.
67. Salomon A, Berry I, Tuite AR, *et al.* Influenza increases invasive meningococcal disease risk in temperate countries. *Clin Microbiol Infect* 2020; 26:1257.e1–1257.e7.
- Epidemiology of influenza and meningococcal meningitis in parallel showing peaks of influenza are followed by outbreaks of meningococcal meningitis.
68. Rustenhoven J, Kipnis J. Bypassing the blood–brain barrier. *Science* 2019; 366:1448–1449.
69. Anil A, Banerjee A. Pneumococcal encounter with the blood–brain barrier endothelium. *Front Cell Infect Microbiol* 2020; 10:590682. doi: 10.3389/fcimb.2020.590682.
70. Zhang Q, Leong SC, McNamara PS, *et al.* Characterisation of regulatory T cells in nasal associated lymphoid tissue in children: relationships with pneumococcal colonization. *PLoS Pathog* 2011; 7:e1002175. doi: 10.1371/journal.ppat.1002175.
71. Orihuela CJ, Mahdavi J, Thornton J, *et al.* Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. *J Clin Invest* 2009; 119:1638–1646.
72. Iovino F, Engelen-Lee JY, Brouwer M, *et al.* plgR and PECAM-1 bind to pneumococcal adhesins RrgA and PspC mediating bacterial brain invasion. *J Exp Med* 2017; 214:1619–1630.
73. Mukerji R, Briles DE. New strategy is needed to prevent pneumococcal meningitis. *Pediatric Infect Dis J* 2020; 39:298–304.
74. Macedo-Ramos H, Campos FS, Carvalho LA, *et al.* Olfactory ensheathing cells as putative host cells for *Streptococcus pneumoniae*: evidence of bacterial invasion via mannose receptor-mediated endocytosis. *Neurosci Res* 2011; 69:308–313.
75. Macedo-Ramos H, Ruiz-Mendoza S, Mariante RM, *et al.* *Streptococcus pneumoniae* resists intracellular killing by olfactory ensheathing cells but not by microglia. *Scientific Rep* 2016; 6:36813. doi: 10.1038/srep36813.
76. Briles DE, Novak L, Hotomi M, *et al.* Nasal colonization with *Streptococcus pneumoniae* includes subpopulations of surface and invasive pneumococci. *Infect Immun* 2005; 73:6945–6951.
77. Hatcher BL, Hale JY, Briles DE. Free sialic acid acts as a signal that promotes *Streptococcus pneumoniae* invasion of nasal tissue and non-hematogenous invasion of the central nervous system. *Infect Immun* 2016; 84:2607–2615.
78. Wall EC, Gritzfeld JF, Scarborough M, *et al.* Genomic pneumococcal load and CSF cytokines are not related to outcome in Malawian adults with meningitis. *J Infect* 2014; 69:440–446.
79. Kanova E, Tkacova Z, Bhide K, *et al.* Transcriptome analysis of human brain microvascular endothelial cells response to *Neisseria meningitidis* and its antigen MafA using RNA-seq. *Scientific Rep* 2019; 9:18763. doi: 10.1038/s41598-019-55409-y.
80. Too LK, Yau B, Baxter AG, *et al.* Double deficiency of toll-like receptors 2 and 4 alters long-term neurological sequelae in mice cured of pneumococcal meningitis. *Scientific Rep* 2019; 9:16189. doi: 10.1038/s41598-019-52212-7.
81. Borkowski J, Li L, Steinmann U, *et al.* *Neisseria meningitidis* elicits a pro-inflammatory response involving IkappaBzeta in a human blood-cerebrospinal fluid barrier model. *J Neuroinflamm* 2014; 11:163. doi: 10.1186/s12974-014-0163-x.

82. van Well GT, Sanders MS, Ouburg S, *et al.* Polymorphisms in Toll-like receptors 2, 4, and 9 are highly associated with hearing loss in survivors of bacterial meningitis. *PLoS One* 2012; 7:e35837. doi: 10.1371/journal.pone.0035837.
83. Mohanty T, Fisher J, Bakochi A, *et al.* Neutrophil extracellular traps in the central nervous system hinder bacterial clearance during pneumococcal meningitis. *Nat Commun* 2019; 10:1667. doi: 10.1038/s41467-019-09040-0.
- Data on NETs from human CSF extrapolated to a murine model to show damaging effects of NETs within the CNS, and efficacy of DNase in improving murine survival.
84. Rajarathnam K, Schnoor M, Richardson RM, Rajagopal S. How do chemokines navigate neutrophils to the target site: dissecting the structural mechanisms and signaling pathways. *Cell Signal* 2018; 54:69–80.
85. Hupp S, Grandgirard D, Mitchell TJ, *et al.* Pneumolysin and the bacterial capsule of *Streptococcus pneumoniae* cooperatively inhibit taxis and motility of microglia. *J Neuroinflamm* 2019; 16:105. doi: 10.1186/s12974-019-1491-7.
- Study showing in-vitro how combined potent pneumococcal virulence factors pneumolysin and capsule combine to inhibit microglial clearance of bacteria in the CNS.
86. Wippel C, Maurer J, Fortsch C, *et al.* Bacterial cytolysin during meningitis disrupts the regulation of glutamate in the brain, leading to synaptic damage. *PLoS Pathogens* 2013; 9:e1003380. doi: 10.1371/journal.ppat.1003380.
87. Wall EC, Gordon SB, Hussain S, *et al.* Persistence of pneumolysin in the cerebrospinal fluid of patients with pneumococcal meningitis is associated with mortality. *Clin Infect Dis* 2012; 54:701–705.
88. Giridharan VV, Generoso JG, Colloidal A, *et al.* Receptor for advanced glycation end products (RAGE) mediates cognitive impairment triggered by pneumococcal meningitis. *Neurotherapeutics* 2020. doi: 10.1007/s13311-020-00917-3.
89. Chen JQ, Li NN, Wang BW, *et al.* Upregulation of CBP by PLY can cause permeability of blood-brain barrier to increase meningitis. *J Biochem Mol Toxicol* 2019; 33:e22333. doi: 10.1002/jbt.22333.
- Study showing direct evidence for the causative role of pneumolysin on BBB leak.
90. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. *Cochrane Database Syst Rev* 2015; (9):CD004405. doi: 10.1002/14651858.CD004405.pub5.
91. Goldberg DW, Tenforde MW, Mitchell HK, Jarvis JN. Neurological sequelae of adult meningitis in Africa: a systematic literature review. *Open Forum Infect Dis* 2018; 5:ofx246. doi: 10.1093/ofid/ofx246.
92. Griffiths MJ, McGill F, Solomon T. Management of acute meningitis. *Clin Med (Lond)* 2018; 18:164–169.
93. Yau B, Hunt NH, Mitchell AJ, Too LK. Blood-brain barrier pathology and CNS outcomes in *Streptococcus pneumoniae* meningitis. *Int J Mol Sci* 2018; 19:3555. doi: 10.3390/ijms19113555.
94. Kasanmoentalib ES, Valls Seron M, Engelen-Lee JY, *et al.* Complement factor H contributes to mortality in humans and mice with bacterial meningitis. *J Neuroinflamm* 2019; 16:279. doi: 10.1186/s12974-019-1675-1.
- Data showing inhibition of C5 improves survival in murine meningitis. Data underpinning current trial of C5 inhibitors in patients.
95. Ribes S, Nessler S, Heide EC, *et al.* The early adaptive immune response in the pathophysiological process of pneumococcal meningitis. *J Infect Dis* 2017; 215:150–158.
96. Mustafa MM, Ramilo O, Saez-Llorens X, *et al.* Cerebrospinal fluid prostaglandins, interleukin 1 beta, and tumor necrosis factor in bacterial meningitis. Clinical and laboratory correlations in placebo-treated and dexamethasone-treated patients. *Am J Dis Children* 1990; 144:883–887.
97. Wall EC, Brownridge P, Laing G, *et al.* CSF levels of elongation factor Tu is associated with increased mortality in Malawian adults with *Streptococcus pneumoniae* meningitis. *Front Cell Infect Microbiol* 2020; 10:603623. doi: 10.3389/fcimb.2020.603623.
- First dual host-pathogen CSF proteome, showing bacterial proteins correlate with clinical outcome, potentially by inhibiting neutrophil-mediated killing of bacteria.
98. Mook-Kanamori BB, Brouwer MC, Geldhoff M, *et al.* Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis. *J Infect* 2014; 68:542–547.
99. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. *N Engl J Med* 2002; 347:1549–1556.
100. Brouwer MC, McIntyre P, de Gans J, *et al.* Corticosteroids for acute bacterial meningitis. *Cochrane Database Syst Rev* 2010; (9):CD004405. doi: 10.1002/14651858.CD004405.pub3.
101. Mogensen TH, Berg RS, Paludan SR, Ostergaard L. Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by *Neisseria meningitidis* and *Streptococcus pneumoniae*. *Infect Immun* 2008; 76:189–197.
102. Lees JA, Ferwerda B, Kremer PHC, *et al.* Joint sequencing of human and pathogen genomes reveals the genetics of pneumococcal meningitis. *Nat Commun* 2019; 10:2176. doi: 10.1038/s41467-019-09976-3.
- Landmark study on host-pathogen GWAS showing host genetic associations with poor clinical outcomes.
103. Panagiotou S, Chaguza C, Yahya R, *et al.* Hypervirulent pneumococcal serotype 1 harbours two pneumolysin variants with differential haemolytic activity. *Sci Rep* 2020; 10:17313. doi: 10.1038/s41598-020-73454-w.
- Data showing differential expression of pneumolysin is important for IPD pathogenesis.
104. Li Y, Metcalf BJ, Chochua S, *et al.* Genome-wide association analyses of invasive pneumococcal isolates identify a missense bacterial mutation associated with meningitis. *Nat Commun* 2019; 10:178. doi: 10.1038/s41467-018-07997-y.
105. Kremer PHC, Lees JA, Ferwerda B, *et al.* Genetic variation in *Neisseria meningitidis* does not influence disease severity in meningococcal meningitis. *Front Med (Lausanne)* 2020; 7:594769. doi: 10.3389/fmed.2020.594769.
106. Minhas V, Aprianto R, McAllister LJ, *et al.* In vivo dual RNA-seq reveals that neutrophil recruitment underlies differential tissue tropism of *Streptococcus pneumoniae*. *Commun Biol* 2020; 3:293. doi: 10.1038/s42003-020-1018-x.
- Key study showing differential tissue tropism and mediation of neutrophil recruitment by *S. pneumoniae*.
107. Minhas V, Harvey RM, McAllister LJ, *et al.* Capacity to utilize raffinose dictates pneumococcal disease phenotype. *mBio* 2019; 10:1. doi: 10.1128/mBio.02596-18.
108. Aprianto R, Slager J, Holsappel S, Veening JW. Time-resolved dual RNA-seq reveals extensive rewiring of lung epithelial and pneumococcal transcriptomes during early infection. *Genome Biol* 2016; 17:198. doi: 10.1186/s13059-016-1054-5.
109. D'Mello A, Riegler AN, Martinez E, *et al.* An in vivo atlas of host-pathogen transcriptomes during *Streptococcus pneumoniae* colonization and disease. *PNAS* 2020; 117:33507–33518.
- Murine and bacterial transcriptomes at different disease sites.
110. Schmidt F, Kakar N, Meyer TC, *et al.* In vivo proteomics identifies the competence regulon and AliB oligopeptide transporter as pathogenic factors in pneumococcal meningitis. *PLoS Pathogens* 2019; 15:e1007987. doi: 10.1371/journal.ppat.1007987.
111. Azad AK, Chakrabarti S, Xu Z, *et al.* Coiled-coil domain containing 3 (CCDC3) represses tumor necrosis factor- α /nuclear factor kappaB-induced endothelial inflammation. *Cell Signal* 2014; 26:2793–2800.
112. van Zeggeren IE, Bijlsma MW, Tanck MW, *et al.* Systematic review and validation of diagnostic prediction models in patients suspected of meningitis. *J Infect* 2020; 80:143–151.
113. Wall EC, Mukaka M, Scarborough M, *et al.* Prediction of outcome from adult bacterial meningitis in a high-HIV-seroprevalence, resource-poor setting using the Malawi Adult Meningitis Score (MAMS). *Clin Infect Dis* 2017; 64:413–419.
114. McGill F, Griffiths MJ, Bonnett LJ, *et al.* Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study. *Lancet Infect Dis* 2018; 18:992–1003.
115. Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. *N Engl J Med* 2001; 345:1727–1733.
116. Michael B, Menezes BF, Cunniffe J, *et al.* Effect of delayed lumbar punctures on the diagnosis of acute bacterial meningitis in adults. *Emerg Med J* 2010; 27:433–438.
117. Glimaker M, Sjolin J, Akesson S, Naucler P. Lumbar puncture performed promptly or after neuroimaging in acute bacterial meningitis in adults: a prospective national cohort study evaluating different guidelines. *Clin Infect Dis* 2018; 66:321–328.
118. Salazar L, Hasbun R. Cranial imaging before lumbar puncture in adults with community-acquired meningitis: clinical utility and adherence to the Infectious Diseases Society of America Guidelines. *Clin Infect Dis* 2017; 64:1657–1662.
119. Costerus JM, Brouwer MC, Splengers MES, *et al.* Cranial computed tomography, lumbar puncture, and clinical deterioration in bacterial meningitis: a nationwide cohort study. *Clin Infect Dis* 2018; 67:920–926.
120. McGill F, Heyderman RS, Michael BD, *et al.* The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. *J Infect* 2016; 72:405–438.
121. van de Beek D, Cabellos C, Dzupova O, *et al.* ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. *Clin Microbiol Infect* 2016; 22(Suppl 3):S37–S62.
122. Tunkel AR, Hasbun R, Bhimraj A, *et al.* 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. *Clin Infect Dis* 2017; 64:e34–e65.
123. Wu HM, Cordeiro SM, Harcourt BH, *et al.* Accuracy of real-time PCR, Gram stain and culture for *Streptococcus pneumoniae*, *Neisseria meningitidis* and *Haemophilus influenzae* meningitis diagnosis. *BMC Infect Dis* 2013; 13:26. doi: 10.1186/1471-2334-13-26.
124. Houlihan CF, Bharucha T, Breuer J. Advances in molecular diagnostic testing for central nervous system infections. *Curr Opin Infect Dis* 2019; 32:244–250.
125. Wilson MR, Sample HA, Zorn KC, *et al.* Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. *N Engl J Med* 2019; 380:2327–2340.
- First report of the clinical utility of NGS for the diagnosis of culture negative meningitis.
126. Costerus JM, Brouwer MC, Bijlsma MW, *et al.* Impact of an evidence-based guideline on the management of community-acquired bacterial meningitis: a prospective cohort study. *Clin Microbiol Infect* 2016; 22:928–933.

127. Wall EC, Mukaka M, Denis B. Goal directed therapy for suspected acute bacterial meningitis in adults and adolescents in sub-Saharan Africa. *PLoS One* 2017; 12:e0186687. doi: 10.1371/journal.pone.0186687.
128. Nhamtumbo AA, Gudo ES, Caierao J, Mungambe AM, *et al.* Serotype distribution and antimicrobial resistance of *Streptococcus pneumoniae* in children with acute bacterial meningitis in Mozambique: implications for a national immunization strategy. *BMC Microbiol* 2016; 16:134. doi: 10.1186/s12866-016-0747-y.
129. Cornick JE, Everett DB, Broughton C, *et al.* Invasive *Streptococcus pneumoniae* in children, Malawi, 2004–2006. *Emerging Infect Dis* 2011; 17:1107–1109.
130. Wen S, Feng D, Chen D, *et al.* Molecular epidemiology and evolution of *Haemophilus influenzae*. *Infect Genet Evol* 2020; 80:104205. doi: 10.1016/j.meegid.2020.104205.
131. Tenforde MW, Mokomane M, Leeme TB, *et al.* Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study. *Lancet Infect Dis* 2019; 19:740–749.
- Data highlighting the excessive mortality from bacterial meningitis in Africa.
132. Kloek AT, Brouwer MC, Schmand B, *et al.* Long-term neurologic and cognitive outcome and quality of life in adults after pneumococcal meningitis. *Clin Microbiol Infect* 2020; 26:1361–1367.
133. Klein M, Koedel U, Pfefferkorn T, *et al.* Arterial cerebrovascular complications in 94 adults with acute bacterial meningitis. *Crit Care* 2011; 15:R281. doi: 10.1186/cc10565.
134. Klein M, Koedel U, Kastenbauer S, *et al.* Delayed cerebral thrombosis after initial good recovery from pneumococcal meningitis: past as prologue: delayed stroke as a parainfectious process of bacterial meningitis? *Neurology* 2010; 75:193author reply 193–4.
135. Engelen-Lee JY, Brouwer MC, Aronica E, van de Beek D. Delayed cerebral thrombosis complicating pneumococcal meningitis: an autopsy study. *Ann Intensive Care* 2018; 8:20. doi: 10.1186/s13613-018-0368-8.
136. Lucas MJ, Brouwer MC, van de Beek D. Delayed cerebral thrombosis in bacterial meningitis: a prospective cohort study. *Intensive Care Med* 2013; 39:866–871.
137. van de Beek D, Farrar JJ, de Gans J, *et al.* Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. *Lancet Neurol* 2010; 9:254–263.
138. Nguyen TH, Tran TH, Thwaites G, *et al.* Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. *N Engl J Med* 2007; 357:2431–2440.
139. Scarborough M, Gordon SB, Whitty CJ, *et al.* Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. *N Engl J Med* 2007; 357:2441–2450.
140. Ajdukiewicz KM, Cartwright KE, Scarborough M, *et al.* Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial. *Lancet Infect Dis* 2011; 11:293–300.
141. Mourvillier B, Tubach F, van de Beek D, *et al.* Induced hypothermia in severe bacterial meningitis: a randomized clinical trial. *JAMA* 2013; 310:2174–2183.
142. Ribes S, Taberner F, Domenech A, *et al.* Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant *Streptococcus pneumoniae* ATCC 51916. *J Antimicrob Chemother* 2005; 56:979–982.
143. Wald-Dickler N, Holtom P, Spellberg B. Busting the myth of 'static vs cidal': a systemic literature review. *Clin Infect Dis* 2018; 66:1470–1474.
144. Grandgirard D, Schurch C, Cottagnoud P, Leib SL. Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. *Antimicrob Agents Chemother* 2007; 51:2173–2178.
145. Kasanmoentalib ES, Valls Seron M, *et al.* Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. *J Neuroinflamm* 2015; 12:149. doi: 10.1186/s12974-015-0372-y.
146. Muri L, Le ND, Zemp J, *et al.* Metformin mediates neuroprotection and attenuates hearing loss in experimental pneumococcal meningitis. *J Neuroinflamm* 2019; 16:156. doi: 10.1186/s12974-019-1549-6.
147. Mai NT, Dobbs N, Phu NH, *et al.* A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. *eLife* 2018; 7. doi: 10.7554/eLife.33478.
148. Liechti FD, Grandgirard D, Leppert D, Leib SL. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. *Infect Immun* 2014; 82:1710–1718.
149. Morton B, Mitsi E, Pennington SH, *et al.* Augmented passive immunotherapy with P4 peptide improves phagocyte activity in severe sepsis. *Shock* 2016; 46:635–641.
150. Jim KK, Engelen-Lee J, van der Sar AM, *et al.* Infection of zebrafish embryos with live fluorescent *Streptococcus pneumoniae* as a real-time pneumococcal meningitis model. *J Neuroinflamm* 2016; 13:188. doi: 10.1186/s12974-016-0655-y.